# MITRE / FLUX NOTES SELECTED CONCEPTS v14.9

EDWIN CHOI, DANIEL REEVES, JUHAN SONIN, 26.JUL.2018




The following concepts explore the visual treatment of placeholders, and explorative concepts for medications. The medication designs should be validated by a provider before further design iteration.

# I PLACEHOLDER TREATMENT

# Visual rules for placeholders

- All placeholders with unfilled structured/unstructured data have a teal background, lighter text, a red underline, and extra spacing on either side.
- Placeholder structured data that was captured via typing or point of capture have a dashed line and regular font style.
- Placeholder structured data that was captured via voice has a dashed line and italic font style.
- · Retrieved data using @ is lighter in color as it is lower priority.
- Users are able to freely type and capture attributes within placeholders, but are not allowed to remove or overwrite the data element (as it changes the meaning of the placeholder and renders it useless).
- If voice captured data within placeholders are edited via typing or through the point of capture interface, it becomes a regular font style.
- When selections are made in point of capture interface, the placeholder text is "refreshed" to reflect the choices.
- When structured data is retrieved via dropdown from the patient summary, the inserted text in the note is lighter in color, just as it would appaer if retrieved using @.



C.

Summary

Timeline

Medication

Allergies

Labs

Social

Disease

status

Dr. Jraker299 referred ms. Debra24 Hernandez98Aj due to pain in left breast. Dr. Jraker299 is ms. Debra24 Hernandez98Aj's primary care physician for 12 years.


## Summary

 $\blacksquare$ 

Ms. Debra24 Hernandez98Aj is a 51year-old menopausal non hispanic or latino woman with invasive ductal carcinoma of the breast, diagnosed on 13 January 2012. Her most recent status, recorded on 15 May 2017, is of worsening, disease progression based on pathology, imaging, and symptoms.

She underwent a lumpectomy. She underwent a sentinel lymph node biopsy on 20 September 2012 which revealed infiltrating poorly differentiated ductal carcinoma, stage IV, estrogen receptor 0, etc.

diagnostic mammogram on 4 October 2013 revealed a 2 cm mass in the right breast at 7 o'clock and an



#### Reason For Visit

Follow-up consultation regarding a procedure related to invasive ductal carcinoma of the breast

Patient #staging

# **History of Present Illness**

HPI for invasive ductal carcinoma of the breast

### Procedure

The patient recently underwent mammography on 6 May 2017 with Dr. Eli Krusk.

Condition:

Invasive ductal

carcinoma of breast

× Close

Fracture

#### Procedure:

# Mammography

Core needle biopsy of breast

Another procedure that happened


Yet another procedure






Sign note

Remove note







Timeline

Medication

Allergies

Labs


Social

Disease

status

 $\equiv \square$ 

0




# Summary

Ms. Debra24 Hernandez98Aj is a 51year-old menopausal non hispanic or latino woman with invasive ductal carcinoma of the breast, diagnosed on 13 January 2012. Her most recent status, recorded on 15 May 2017, is of worsening, disease progression based on pathology, imaging, and symptoms.

She underwent a lumpectomy. She underwent a sentinel lymph node biopsy on 20 September 2012 which revealed infiltrating poorly differentiated ductal carcinoma, stage IV, estrogen receptor 0, etc.

diagnostic mammogram on 4 October 2013 revealed a 2 cm mass in the right breast at 7 o'clock and an



Date of birth Admin. sex Location

Boston, MA

Ductal carcinoma of the breast -

Shared 0

Q Debra24 search...

Summary

Timeline

Medication

Allergies

Labs

Dr. Jraker299 referred ms. Debra24 Hernandez98Aj due to pain in left breast. Dr. Jraker299 is ms. Debra24 Hernandez98Aj's primary care physician for 12 years.

 $\equiv \blacksquare$ 

## Summary

Ms. Debra24 Hernandez98Aj is a 51year-old menopausal non hispanic or latino woman with invasive ductal carcinoma of the breast, diagnosed on 13 January 2012. Her most recent status, recorded on 15 May 2017, is of worsening, disease progression based on pathology, imaging, and symptoms.

She underwent a lumpectomy. She underwent a sentinel lymph node biopsy on 20 September 2012 which revealed infiltrating poorly differentiated ductal carcinoma, stage IV, estrogen receptor 0, etc.

diagnostic mammogram on 4 October 2013 revealed a 2 cm mass in the right breast at 7 o'clock and an



#### 4 Assessment


Although her #disease status is #stable #as of #1/30/2018, recommending to half after 5 cycles due to #toxicity #grade 3 #myalgia and #toxicity #grade 3 #peripheral motor neuropathy attributed to paclitaxel.

Patient's staging is IIIA based on T0, N2, and has M0. Given the current data, I determine disease status

The patient is deceased or not deceased. A Port-A-Cath was replaced today. She will start induction chemotherapy with trastuzumab due to low volume of metastatic disease, beginning on October 17, 2017. A section of @ retrieved data from the patient record.

The patient is exhibiting toxicity The patient is also exhibiting toxicity nausea. The patient's receptors are as follows, HER2 is positive. ER is positive. PR is positive. A section of @ retrieved data from the patient record. The patient is interested in clinical trial enrollment. Enrolled in PATINA.

Ask patient about how her brother is doing.



Ignore toxicity

4 corrections

Nausea was previously captured on 8 May 2018

#### Grade

#### Attribution



Ignore attribution

#### Continuity

Sign note

Continuing toxicity

End toxicity

Remove note

Remove 4 unfilled elements after signing


Disease status

Social

# 2 MEDICATION EXPLORATION

Concept: Summary view with collapsed dates

Assumption: this subsection includes only current course for start time



"..." brings up a detail pane, or a single supporting next line, that gives more information such as prescribing physician and administration directions.

Concept: Expanded view now displays each request and an option for more details on each request. Assumption: this subsection includes only current course

<b>Active Medications</b>	Dosage			Dates	Progress	Changes	Мо	ore
MedicationMedA	10 mg qd	10	20 25	24 Feb 2018	end: 12 Apr 2018	reduced, toxicity		~
	20 mg qd		20	15 Feb 2018		increased, ineffective		
	10 mg	10		10 Jan 2018	start for 3 months			
ChemoBB	150 mg/m2 <sup>1</sup> q3weeks	50	125	2 Feb 2018	3 of 5 cycles			

Concept: Expanded view now displays each request and an option for more details on each request. Assumption: this subsection includes ALL the courses

Active Medications	Dosage		Dates	Progress	Changes	Mor	e
MedicationMedA	10 mg qd	20 25	24 Feb 2018	end: 12 Apr 2018	reduced, toxicity		~
	20 mg qd	20	15 Feb 2018		increased, ineffective		
	10 mg	10	10 Jan 2018	start for 3 months			
	10 mg qd	10	5 Jul 2016	finished: 6 Sep 2016	reduced, toxicity		
	20 mg qd	20	4 Jun 2016	start for 3 months			
ChemoBB	150 mg/m2 <sup>1</sup> q3weeks	50 125	2 Feb 2018	3 of 5 cycles			